RESUMEN
OBJECTIVES: We had for aim to determine the characteristics of carbapenemase-producing enterobacteria (CPE) carriers and to assess the economic impact of isolation measures leading to loss of activity (closed beds, prolonged hospital stays) and additional personnel hours. PATIENTS AND METHODS: We conducted a retrospective study for 2years (2012/2013), in a French general hospital, focusing on CPE carriers with clinical case description. The costs were estimated by comparing the activity of concerned units (excluding the ICU) during periods with CPE carriers or contacts, during the same periods of the year (n-1), plus additional hours and rectal swabs. RESULTS: Sixteen EPC carriers were identified: 10 men and 6 women, 65±10years of age. Seven patients acquired EPC in hospital during 2 outbreaks in 2012. Four patients presented with an infection (peritonitis, catheter infection, and 2 cases of obstructive pyelonephritis) with a favorable outcome. The median length of stay was 21days [4,150]. Six patients died, 1 death was indirectly due to CPE because of inappropriate empiric antibiotic therapy. A decrease in activity was observed compared to the previous year with an estimated 547,303 loss. The 1779 additional hours cost 63,870, and 716 screening samples cost 30,931. The total additional cost was estimated at 642,104 for the institution. CONCLUSIONS: Specialized teams for CPE carriers and isolation of contact patients, required to avoid/control epidemics, have an important additional cost. An appreciation of their support is needed, as well as participation of rehabilitation units.
Asunto(s)
Proteínas Bacterianas/análisis , Portador Sano , Infecciones por Enterobacteriaceae/epidemiología , Enterobacteriaceae/enzimología , Costos de Hospital/estadística & datos numéricos , Hospitales Generales/estadística & datos numéricos , Resistencia betalactámica , beta-Lactamasas/análisis , Anciano , Carbapenémicos/farmacología , Portador Sano/economía , Portador Sano/epidemiología , Infección Hospitalaria/economía , Infección Hospitalaria/epidemiología , Infección Hospitalaria/microbiología , Brotes de Enfermedades/economía , Enterobacteriaceae/genética , Enterobacteriaceae/aislamiento & purificación , Infecciones por Enterobacteriaceae/economía , Infecciones por Enterobacteriaceae/microbiología , Femenino , Francia/epidemiología , Unidades Hospitalarias/economía , Hospitales Generales/economía , Humanos , Control de Infecciones/economía , Unidades de Cuidados Intensivos/economía , Infecciones por Klebsiella/economía , Infecciones por Klebsiella/epidemiología , Infecciones por Klebsiella/microbiología , Klebsiella pneumoniae/enzimología , Tiempo de Internación/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Aislamiento de Pacientes/economía , Personal de Hospital/economía , Estudios RetrospectivosRESUMEN
Despite standardization, marked interindividual variation in the severity of the disulfiram-alcohol reaction (DAR) has been observed. We studied the DAR in 51 consecutive alcoholics with (n = 16) and without (n = 35) significant alcoholic liver disease. Clinical signs of the DAR were much weaker in the patients with compared with those patients without liver disease. Because acetaldehyde is thought to be the main cause of the DAR, we studied ethanol and acetaldehyde kinetics in 13 patients (6 females, 7 males) with alcoholic liver disease (documented by biopsy, clinical and/or radiological findings, and by quantitative liver function) [galactose elimination capacity (GEC) 4.2 +/- SD 1.0 mg/min/kg; aminopyrine breath test (ABT) 0.14 +/- 0.10% dose x kg/mmol CO2] and 13 age- and sex-matched controls (alcoholics without significant liver disease, GEC 7.1 +/- 0.7; ABT 0.81 +/- 0.35). Clinical signs of acetaldehyde toxicity during the DAR (flush, nausea, tachycardia, and blood pressure drop) were absent in alcoholic liver disease, but clearly evident in controls. Blood ethanol kinetics were similar in both groups, Cmax and area under the concentration-time curve (AUC) being 6.27 +/- 1.82 and 368.9 +/- 72.9 mmol x min/liter in alcoholic liver disease, and 6.62 +/- 1.71 and 377.6 +/- 124.5 in controls, respectively. In contrast, there was a strong (p < 0.001) difference in Cmax and AUC of acetaldehyde, respective values being 33.46 +/- 21.52 and 1463.8 +/- 762.5 mumol x min/liter in alcoholic liver disease, and 110.87 +/- 56.00 and 4162.0 +/- 2424.6 in controls.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Acetaldehído/farmacocinética , Disulfiram/efectos adversos , Etanol/farmacocinética , Hepatopatías Alcohólicas/sangre , Adulto , Anciano , Terapia Combinada , Disulfiram/administración & dosificación , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Hepatopatías Alcohólicas/rehabilitación , Masculino , Persona de Mediana EdadRESUMEN
A patient with myeloma nephropathy and acute, probably diclofenac-induced renal failure developed a neuroleptic malignant syndrome (NMS) during treatment with metoclopramide and neuroleptics. These drugs were withdrawn, symptomatic treatment of NMS was started and the patient was hemodialyzed because of uremia. During hemodialysis, the patient's condition improved dramatically and NMS did not recur during her further stay in the hospital. The temporal relationship between metoclopramide administration and the development of NMS, as well as the rapid reversal of NMS, suggest that NMS in this patient was caused by metoclopramide and not by neuroleptic drugs. Thus, metoclopramide should be used with caution in patients with renal failure and patients should be monitored closely for the development of neuroleptic malignant syndrome. Hemodialysis may be therapeutically effective in certain patients with metoclopramide-induced NMS.
Asunto(s)
Anuria/inducido químicamente , Clorpromazina/efectos adversos , Metoclopramida/efectos adversos , Síndrome Neuroléptico Maligno/etiología , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Femenino , Humanos , Neoplasias Renales/complicaciones , Neoplasias Renales/tratamiento farmacológico , Plasmacitoma/complicaciones , Plasmacitoma/tratamiento farmacológicoRESUMEN
Two young human immunodeficiency virus (HIV)-infected patients, a 25-year-old woman and a 26-year-old man, consumed large amounts of germanium lactate citrate 18% as an "immunostimulant" for 9 months. The woman, who had stage II HIV infection, developed severe renal dysfunction (creatinine clearance, 7 mL/min/1.73 m2) and slight proteinuria (0.28 g/d) after ingesting 260 g germanium lactate citrate 18%. Hepatomegaly with liver dysfunction (SGOT, 102 U/L; gamma-glutamyl transferase (GT), 159 U/L) and lactic acidosis (plasma lactate, 7.3 mmol/L) developed simultaneously. Renal biopsy revealed tubulointerstitial nephropathy with vacuolar cell degeneration and periodic acid-Schiff-positive intracellular deposits mainly in distal tubules. Liver biopsy disclosed severe hepatic steatosis; liver function tests returned to normal within 5 weeks. Since renal failure persisted for 2 years after ingestion of germanium (creatinine clearance, 14 mL/min/1.73 m2; proteinuria, 0.84 g/d), a second renal biopsy was performed, which showed marked but focal distal tubular atrophy and slight interstitial fibrosis. The male patient, who had stage III HIV infection, had ingested the same compound; he presented with a creatinine clearance of 43 mL/min/m2 and proteinuria of 0.36 g/d. Renal biopsy disclosed tubulointerstitial changes similar to those found in the female patient. After 9 months off germanium, creatinine clearance remained unchanged. Neutron activation analysis of all biopsy specimens in both cases documented germanium concentrations 10 to 70 times normal in renal tissue and 140 times normal in liver tissue.
Asunto(s)
Germanio/efectos adversos , Infecciones por VIH/tratamiento farmacológico , Nefritis Intersticial/inducido químicamente , Adulto , Enfermedad Crónica , Femenino , Germanio/administración & dosificación , Humanos , Túbulos Renales/patología , Túbulos Renales/ultraestructura , Masculino , Microscopía Electrónica , Nefritis Intersticial/patología , Factores de TiempoRESUMEN
Reports mainly from Japan, recommend germanium (Ge)-containing compounds as "anti-cancer" and "immunostimulatory" remedies. We report on a 25-tear-old woman with stage II HIV disease who consumed a total of 47 g Ge as Ge-lactate-citrate 18%. She developed severe renal insufficiency (creatinine clearance 7 ml/min/1.73 m2, proteinuria 0.28 g/d) and hepatomegaly. Biopsies revealed tubulointerstitial nephropathy with vacuolar degeneration, mainly of distal tubular epithelia, and severe liver steatosis. Tissue Ge content in kidney and liver biopsy specimens was increased 68-and 140 fold respectively. In agreement with previous reports, renal dysfunction persisted 9 months later (creatinine clearance 11 ml/min/1.73 m2).
Asunto(s)
Lesión Renal Aguda/inducido químicamente , Germanio/efectos adversos , Infecciones por VIH/tratamiento farmacológico , Compuestos Organometálicos/efectos adversos , Adulto , Citratos , Hígado Graso/inducido químicamente , Femenino , Germanio/uso terapéutico , Hepatomegalia/inducido químicamente , Humanos , Lactatos , Compuestos Organometálicos/uso terapéuticoRESUMEN
The image of the chronic alcohol patient has changed. Diagnosis is only possible if the doctor assumes alcohol abuse in all his patients. The diagnosis can only be made taking psychiatric, somatic and psychosocial aspects into consideration. Because of the tendency of the patient to deny, an independent history is necessary. Questionnaires, such as the 'Münchner Alkoholismustest', may be helpful. Therapy by the family physician is initiated with a careful somatic, psychiatric and psychosocial work-up, counselling and care. An important factor is the close collaboration between physician and social worker.